Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

Details 詳細情報について

• CRID

  1360016869254392192

• DOI

  10.1016/s0959-8049(16)32607-7

• ISSN

  09598049

• Web Site

  https://api.elsevier.com/content/article/PII:S0959804916326077?httpAccept=text/plain

  https://api.elsevier.com/content/article/PII:S0959804916326077?httpAccept=text/xml

• Data Source

  • Crossref